--- title: "Amylyx Pharmaceuticals (AMLX) news: offering" url: "https://aibio.space/companies/amylyx-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AMLX offering news: Amylyx Pharmaceuticals launches $350,000,000 common stock offering. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), United States." --- AMLX Amylyx Pharmaceuticals, Inc. NASDAQ · United States # Amylyx Pharmaceuticals (AMLX) news AMLX offering news Financings · 2026-08-18 ## [Amylyx Pharmaceuticals launches $350,000,000 common stock offering](https://aibio.space/news/amylyx-pharmaceuticals-launches-350-000-000-common-stock-offering/) Amylyx's final supplement prices 14,090,000 shares at $35.500 for $500,195,000 before costs, above the $350,000,000 in the first filing. The company announced Phase 3 topline results the same day. ## Latest Amylyx Pharmaceuticals news We have not published a story on Amylyx Pharmaceuticals yet. When there is news, it will appear here. ## Amylyx Pharmaceuticals at a glance - **Ticker**: AMLX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $250.8 million ### Related companies - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) NASDAQ: SKYE - [Evolus](https://aibio.space/companies/evolus/) NASDAQ: EOLS - [Arcutis Biotherapeutics](https://aibio.space/companies/arcutis-biotherapeutics/) NASDAQ: ARQT - [Oncology Pharma](https://aibio.space/companies/oncology-pharma/) OTC: ONPH - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) NASDAQ: BLSM - [Johnson & Johnson](https://aibio.space/companies/johnson-johnson/) NYSE: JNJ - [Werewolf Therapeutics](https://aibio.space/companies/werewolf-therapeutics/) NASDAQ: HOWL ### Also on NASDAQ - [NEUROONE MEDICAL TECHNOLOGIES](https://aibio.space/companies/neuroone-medical-technologies/) NMTC - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) OVID - [Fulgent Genetics](https://aibio.space/companies/fulgent-genetics/) FLGT - [NEPHROS INC](https://aibio.space/companies/nephros/) NEPH - [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NRSN - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NBP ## What Amylyx Pharmaceuticals does Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases. Its lead investigational asset, avexitide, is a first-in-class GLP-1 receptor antagonist. It has been evaluated for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism. The FDA has granted avexitide Breakthrough Therapy Designation for both PBH and hyperinsulinemic hypoglycemia, Rare Pediatric Disease Designation in congenital hyperinsulinism, and Orphan Drug Designation for hyperinsulinemic hypoglycemia. PBH is estimated to affect approximately 8% of people in the U.S. who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass, and there are no approved therapies for it. The Phase 3 LUCIDITY trial is a randomized, double-blind, placebo-controlled study in participants with PBH after Roux-en-Y gastric bypass surgery. Recruitment is complete, with topline data expected in Q3 2026 and a commercial launch in 2027 if approved. The company says it matches investigational therapies to diseases based on mechanistic rationale, clinical outcomes and biomarkers, regardless of modality. | Product or program | What it is | Stage | |---|---|---| | Avexitide | First-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism | Phase 3 | Summarised from the company's [10-K filed Mar 3, 2026](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/amlx-20251231.htm). ## Amylyx Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$90.4 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | [$104.1 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | | Net income (loss) | [-$144.7 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | [-$301.7 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | | Cash from operations | [-$123.3 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | [-$167.6 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | | Cash and equivalents | [$226.7 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336682/) | [$77.4 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | | Short-term investments | [$90.3 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336682/) | [$99.1 million](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $49.3 million, plus short-term investments of $201.4 million, $250.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Amylyx Pharmaceuticals Has Amylyx Pharmaceuticals raised money recently? Our latest story on this, dated Aug 18, 2026: "Amylyx Pharmaceuticals launches $350,000,000 common stock offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/amylyx-pharmaceuticals-launches-350-000-000-common-stock-offering/). What is the ticker symbol of Amylyx Pharmaceuticals? Amylyx Pharmaceuticals, Inc. trades under the ticker AMLX on NASDAQ. Where is Amylyx Pharmaceuticals listed? Amylyx Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Amylyx Pharmaceuticals? The SEC Central Index Key (CIK) for Amylyx Pharmaceuticals, Inc. is 1658551. Its filings are on SEC EDGAR. How many shares does Amylyx Pharmaceuticals have outstanding? 111,423,048 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Amylyx Pharmaceuticals listed under? Our directory records Amylyx Pharmaceuticals, Inc. under United States. What does Amylyx Pharmaceuticals do? Our directory classifies Amylyx Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Amylyx Pharmaceuticals? The ISIN recorded for Amylyx Pharmaceuticals, Inc. is US03237H1014. Does aibio.space cover Amylyx Pharmaceuticals? aibio.space lists Amylyx Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Amylyx Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Amylyx Pharmaceuticals develop? Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases. Its lead investigational asset, avexitide, is a first-in-class GLP-1 receptor antagonist. What is Avexitide from Amylyx Pharmaceuticals? Avexitide: First-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism Stage: Phase 3. Is Amylyx Pharmaceuticals profitable? Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7 million for the fiscal year ended Dec 31, 2025, and used $123.3 million of cash in operations, per its annual report to the SEC. How much does Amylyx Pharmaceuticals spend on research and development? $90.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Amylyx Pharmaceuticals have? $250.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Amylyx Pharmaceuticals Members talk about Amylyx Pharmaceuticals (AMLX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Amylyx Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-18 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1658551/000119312526355696/d180581d424b5.htm) 2. 2025-09-09 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1658551/000119312525199270/d27062d424b5.htm) 3. 2025-01-10 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1658551/000119312525004002/d922830d424b5.htm) 4. 2024-11-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1658551/000095017024122833/amlx-20240930.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AMLX on TradingView](https://www.tradingview.com/symbols/NASDAQ-AMLX/). ## SEC filings and registration - **SEC name**: Amylyx Pharmaceuticals, Inc. - **CIK**: 1658551 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AMLX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142 - **Phone**: 617-682-0917 - **Shares outstanding**: 111,423,048 as of 2026-07-27 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/d160615d8k.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/d179247d8k.htm) filed 2026-08-20 - [424B5](https://www.sec.gov/Archives/edgar/data/1658551/000119312526359416/d180581d424b5.htm) filed 2026-08-20 - [424B5](https://www.sec.gov/Archives/edgar/data/1658551/000119312526355696/d180581d424b5.htm) filed 2026-08-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526354793/d184004d8k.htm) filed 2026-08-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/d180533d8k.htm) filed 2026-08-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336682/amlx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-20260806.htm) filed 2026-08-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001658551), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Amylyx Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AMLX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Amylyx Pharmaceuticals, Inc. - **Ticker**: AMLX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03237H1014 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AMLX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/amylyx-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Amylyx Pharmaceuticals (AMLX) news: offering", 2026-10-31, https://aibio.space/companies/amylyx-pharmaceuticals/